Loss of Pfizer (BNT162b2) Vaccine-Induced Antibody Responses against the SARS-CoV-2 Omicron Variant in Adolescents and Adults
Article
[키워드] Adolescent
adolescents
adolescents and adult
adolescents and adults
Adults
age
antibody
Antibody binding
antibody binding titers
approved
Beta
binding
binding antibody
BNT162b2
BNT162b2 vaccine
booster
booster dose
booster vaccination
breadth
changes in
children
circulating
clinical trial
Cohort
Coverage
COVID-19
Delta
demonstrated
dose
drug
Effectiveness
Efficacy
evaluate
FDA
food
Gamma
highlight
Hospitalization
humoral immune response
lack
less
Loss
magnitude
mounted
mRNA vaccine
neutralization
Neutralizing antibody response
omicron
Omicron (B.1.1.529)
pandemic
pediatric
Pfizer
Pfizer-BioNTech
Pfizer-BioNTech (BNT162b2)
plasma
populations
PROTECT
reduction
reported
Research
response
responses against
robust
SARS-CoV-2
seasonal beta coronavirus
the antibody response
the SARS-CoV-2
the vaccine
vaccination
Vaccine
vaccine-induced antibody response
Vaccine-induced immunity
variant
variant of concerns (VOCs)
variants
viral variant
Virus neutralization
virus spike protein
VoC
VOCs
while
wild-type SARS-CoV-2
[DOI] 10.1128/jvi.00582-22 PMC 바로가기
[DOI] 10.1128/jvi.00582-22 PMC 바로가기